The Principles of Clinical Cytogenetics - Extra Materials - Springer

Cytogenetics of Solid Tumors 451
175. Mascarello, J.T., Cajulis, T.R., Krous, H.F., and Carpenter, P.M. (1994) Presence or absence of trisomy 11 is correlated
with histologic subtype in congenital mesoblastic nephroma. Cancer Genet. Cytogenet. 77, 50–54.
176. Wang, S., Saboorian, M.H., Frenkel, E., Hynan, L., Gokaslan, S.T., and Ashfaq, R. (2000) Laboratory assessment of
the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay
with fluorescence in situ hybridisation assays. J. Clin. Pathol. 53, 374–381.
177. Tanner, M., Gancberg, D., Di Leo, A., et al. (2000) Chromogenic in situ hybridization: a practical alternative for
fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am.
J. Pathol. 157, 1467–1472.
178. Zhao, J., Wu, R., Au, A., Marquez, A., Yu, Y., and Shi, Z. (2002) Determination of HER2 gene amplification by
chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod. Pathol. 15, 657–665.
179. Vocke, C.D., Pozzatti, R.O., Bostwick, D.G., et al. (1996) Analysis of 99 microdissected prostate carcinomas reveals a
high frequency of allelic loss on chromosome 8p12-21. Cancer Res. 56, 2411–2416.
180. Huang, S.F., Xiao, S., Renshaw, A.A., Loughlin, K.R., Hudson, T.J., and Fletcher, J.A. (1996) Fluorescence in situ
hybridization evaluation of chromosome deletion patterns in prostate cancer. Am. J. Pathol. 149, 1565–1573.
181. Cher, M.L., Ito, T., Weidner, N., Carroll, P.R., and Jensen, R.H. (1995) Mapping of regions of physical deletion on
chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J. Urol. 153, 249–254.
182. Gray, I.C., Phillips, S.M., Lee, S.J., Neoptolemos, J.P., Weissenbach, J., and Spurr, N.K. (1995) Loss of the chromosomal
region 10q23–25 in prostate cancer. Cancer Res. 55, 4800–4803.
183. Matsuyama, H., Pan, Y., Oba, K., et al. (2003) The role of chromosome 8p22 deletion for predicting disease progression
and pathological staging in prostate cancer. Aktuelle Urol. 34, 247–249.
184. Matsuyama, H., Pan, Y., Yoshihiro, S., et al. (2003) Clinical significance of chromosome 8p, 10q, and 16q deletions in
prostate cancer. Prostate 54, 103–111.
185. Nemoto, R., Nakamura, I., Uchida, K., and Harada, M. (1995) Numerical chromosome aberrations in bladder cancer
detected by in situ hybridization. Br. J. Urol. 75, 470–476.
186. Stadler, W.M., Sherman, J., Bohlander, S.K., et al. (1994) Homozygous deletions within chromosomal bands 9p21-22
in bladder cancer. Cancer Res. 54, 2060–2063.
187. Sandberg, A.A. and Berger, C.S. (1994) Review of chromosome studies in urological tumors. II. Cytogenetics and
molecular genetics of bladder cancer. J. Urol. 151, 545–560.
188. Skacel, M., Fahmy, M., Brainard, J.A., et al. (2003) Multitarget fluorescence in situ hybridization assay detects transitional
cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J. Urol.
169, 2101–2105.
189. Stadler, W.M., Steinberg, G., Yang, X., Hagos, F., Turner, C., and Olopade, O.I. (2001) Alterations of the 9p21 and
9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin. Cancer Res.
7, 1676–1682.
190. Anonymous (1988) Occupational bladder cancer: a guide for clinicians. The BAUS Subcommittee on Industrial Bladder
Cancer. Br. J. Urol. 61, 183–191.
191. Schulte, P.A., Ringen, K., Hemstreet, G.P., Aet al. (1986) Risk factors for bladder cancer in a cohort exposed to aromatic
amines. Cancer 58, 2156–2162.
192. Hartge, P., Hoover, R., and Kantor, A. (1985) Bladder cancer risk and pipes, cigars, and smokeless tobacco. Cancer 55,
901–906.
193. El-Bolkainy, M.N., Mokhtar, N.M., Ghoneim, M.A., and Hussein, M.H. (1981) The impact of schistosomiasis on the
pathology of bladder carcinoma. Cancer 48, 2643–2648.
194. Reifenberger, G. and Louis, D.N. (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.
J. Neuropathol. Exp. Neurol. 62, 111–126.
195. Ino, Y., Betensky, R.A., Zlatescu, M.C., et al. (2001) Molecular subtypes of anaplastic oligodendroglioma: implications
for patient management at diagnosis. Clin. Cancer Res. 7, 839–845.
196. Eller, J.L., Longo, S.L., Hicklin, D.J., and Canute, G.W. (2002) Activity of anti-epidermal growth factor receptor
monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 51, 1005–1013.
197. Bosl, G.J., Ilson, D.H., Rodriguez, E., Motzer, R.J., Reuter, V.E., and Chaganti, R.S. (1994) Clinical relevance of the
i(12p) marker chromosome in germ cell tumors. J. Natl. Cancer Inst. 86, 349–355.
198. Mertens, F., Johansson, B., and Mitelman, F. (1994) Isochromosomes in neoplasia. Genes Chromosomes Cancer 10,
221–230.